Drug Trial Radar · NCT05239143
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Feb 15, 2022
Primary completion
Apr 2039
Study completion Apr 2039
Sponsor
- Lead sponsor
- Poseida Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
Conditions
- Breast Cancer
- Ovarian Cancer
- Non Small Cell Lung Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Renal Cell Carcinoma
- Nasopharyngeal Cancer
- Head and Neck Squamous Cell Carcinoma
- Gastric Cancer
Interventions
P-MUC1C-ALLO1 CAR-T cellsBiological
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.
RimiducidDrug
Rimiducid (safety switch activator) may be administered as indicated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of P-MUC1C-ALLO1Time frame: Baseline through Day 28
- Evaluate the overall safety and tolerability profile of P-MUC1C-ALLO1Time frame: Baseline through 15 years
- Evaluate the preliminary efficacy of P-MUC1C-ALLO1Time frame: Baseline through 15 years
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
University of California, Irvine Medical Center
Irvine, California
Cedars Sinai Medical Center
Los Angeles, California
University of California, San Diego
San Diego, California
University of California, San Francisco
San Francisco, California
Sarah Cannon Research Institute at HealthONE
Denver, Colorado
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Kansas Cancer Center
Westwood, Kansas
Cancer Center of Kansas
Wichita, Kansas
University of Maryland Cancer Center
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
University of Nebraska Medical Center
Omaha, Nebraska
Montefiore Medical Center
The Bronx, New York
MD Anderson Cancer Center
Houston, Texas
NEXT Oncology
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.